VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q74258276 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241020233203.0
008 241020nneanz||abbn n and d
035 ‎‡a (WKP)Q74258276‏
024 ‎‡a 0000-0001-8162-0209‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q74258276‏
100 0 ‎‡a Adolfo Díez-Pérez‏ ‎‡c researcher‏ ‎‡9 en‏
400 0 ‎‡a Díez-Pérez A‏ ‎‡9 es‏
400 0 ‎‡a Díez-Pérez A‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's A Haplotype-Based Analysis of theLRP5Gene in Relation to Osteoporosis Phenotypes in Spanish Postmenopausal Women‏
670 ‎‡a Author's A meta-analysis of the association of fracture risk and body mass index in women‏
670 ‎‡a Author's A new SNP in a negative regulatory region of the CYP19A1 gene is associated with lumbar spine BMD in postmenopausal women.‏
670 ‎‡a Author's Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis‏
670 ‎‡a Author's AI-related BMD variation in actual practice conditions: A prospective cohort study.‏
670 ‎‡a Author's Alendronate and etidronate do not regulate interleukin 6 and 11 synthesis in normal human osteoblasts in culture.‏
670 ‎‡a Author's Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis‏
670 ‎‡a Author's An increased rate of falling leads to a rise in fracture risk in postmenopausal women with self-reported osteoarthritis: a prospective multinational cohort study (GLOW)‏
670 ‎‡a Author's Analyses of RANK and RANKL in the post-GWAS context: functional evidence of vitamin D stimulation through a RANKL distal region.‏
670 ‎‡a Author's Analysis of three functional polymorphisms in relation to osteoporosis phenotypes: replication in a Spanish cohort.‏
670 ‎‡a Author's Ankylosing spondylitis confers substantially increased risk of clinical spine fractures: a nationwide case-control study.‏
670 ‎‡a Author's Ankylosing spondylitis is associated with an increased risk of vertebral and nonvertebral clinical fractures: a population-based cohort study.‏
670 ‎‡a Author's Applications of a New Handheld Reference Point Indentation Instrument Measuring Bone Material Strength‏
670 ‎‡a Author's Are the High Hip Fracture Rates Among Norwegian Women Explained by Impaired Bone Material Properties?‏
670 ‎‡a Author's Association between Colles' fracture and low bone mass: age-based differences in postmenopausal women‏
670 ‎‡a Author's Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and O‏
670 ‎‡a Author's Bisphosphonates.‏
670 ‎‡a Author's Bone Density, Microarchitecture, and Tissue Quality Long-term After Kidney Transplant.‏
670 ‎‡a Author's Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer.‏
670 ‎‡a Author's Bone Mass of a 113-Year-Old Man‏
670 ‎‡a Author's Bone mass, vitamin D deficiency and hyperparathyroidism in congestive heart failure.‏
670 ‎‡a Author's Bone material strength is associated with areal BMD but not with prevalent fractures in older women‏
670 ‎‡a Author's Bone metabolism and histomorphometric changes in rheumatoid arthritis‏
670 ‎‡a Author's Bone mineral density referral for dual-energy X-ray absorptiometry using quantitative ultrasound as a prescreening tool in postmenopausal women from the general population: a cost-effectiveness analysis‏
670 ‎‡a Author's Bone Tissue Properties Measurement by Reference Point Indentation in Glucocorticoid-Induced Osteoporosis‏
670 ‎‡a Author's Brief Report: HIV Infection Is Associated With Worse Bone Material Properties, Independently of Bone Mineral Density.‏
670 ‎‡a Author's Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW)‏
670 ‎‡a Author's Burden of pelvis fracture: a population-based study of incidence, hospitalisation and mortality.‏
670 ‎‡a Author's Changing trends in the epidemiology of hip fracture in Spain.‏
670 ‎‡a Author's Characteristics associated with anti-osteoporosis medication use: data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort.‏
670 ‎‡a Author's Circulating sclerostin and estradiol levels are associated with inadequate response to bisphosphonates in postmenopausal women with osteoporosis.‏
670 ‎‡a Author's COL1A1, ESR1, VDR and TGFB1 polymorphisms and haplotypes in relation to BMD in Spanish postmenopausal women‏
670 ‎‡a Author's COL1A1 haplotypes and hip fracture.‏
670 ‎‡a Author's Comparison of the effects of ossein-hydroxyapatite complex and calcium carbonate on bone metabolism in women with senile osteoporosis: a randomized, open-label, parallel-group, controlled, prospective study.‏
670 ‎‡a Author's Correction: Large-Scale Evidence for the Effect of the COLIA1 Sp1 Polymorphism on Osteoporosis Outcomes: The GENOMOS Study‏
670 ‎‡a Author's Current and future treatments of secondary osteoporosis‏
670 ‎‡a Author's CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss.‏
670 ‎‡a Author's Development of a short osteoporosis quality of life questionnaire by equating items from two existing instruments.‏
670 ‎‡a Author's [Development of the ECOS-16 clinical questionnaire for the assessment of the quality of life in patients with osteoporosis]‏
670 ‎‡a Author's Discriminative capacity of calcaneal quantitative ultrasound and of osteoporosis and fracture risk factors in postmenopausal women with osteoporotic fractures.‏
670 ‎‡a Author's Drug utilization in patients with OA: a population-based study.‏
670 ‎‡a Author's Early (1-year) Discontinuation of Different Anti-osteoporosis Medications Compared: A Population-Based Cohort Study‏
670 ‎‡a Author's Effect of IL-1beta, PGE(2), and TGF-beta1 on the expression of OPG and RANKL in normal and osteoporotic primary human osteoblasts.‏
670 ‎‡a Author's [Effect of tobacco smoking on leptin serum levels and its relationship with steroid hormones and bone mineral density]‏
670 ‎‡a Author's Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.‏
670 ‎‡a Author's Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women‏
670 ‎‡a Author's Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW).‏
670 ‎‡a Author's Erratum to “The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis‏
670 ‎‡a Author's Erratum to “The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)” [Ma‏
670 ‎‡a Author's Evaluation of calcaneal quantitative ultrasound in a primary care setting as a screening tool for osteoporosis in postmenopausal women‏
670 ‎‡a Author's Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women‏
670 ‎‡a Author's Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW).‏
670 ‎‡a Author's [Fragility non-spinal fractures in a cohort of 5,201 women aged 65 years and older during a 3-year follow-up]‏
670 ‎‡a Author's FRAX® thresholds to identify people with high or low risk of osteoporotic fracture in Spanish female population‏
670 ‎‡a Author's Functional analysis of the I.3, I.6, pII and I.4 promoters of CYP19 (aromatase) gene in human osteoblasts and their role in vitamin D and dexamethasone stimulation.‏
670 ‎‡a Author's Functional Assessment of Coding and Regulatory Variants From the <i>DKK1</i> Locus‏
670 ‎‡a Author's Genetic analysis of high bone mass cases from the BARCOS cohort of Spanish postmenopausal women‏
670 ‎‡a Author's HIV infection, bone metabolism, and fractures.‏
670 ‎‡a Author's In vitro performance of ceramic coatings obtained by high velocity oxy-fuel spray‏
670 ‎‡a Author's Inadequate responders to osteoporosis treatment: proposal for an operational definition.‏
670 ‎‡a Author's Incidence and Predictors of Multiple Fractures Despite High Adherence to Oral Bisphosphonates: A Binational Population-Based Cohort Study.‏
670 ‎‡a Author's Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of age, gender and osteoarthritis affecting other joints.‏
670 ‎‡a Author's Incident type 2 diabetes and hip fracture risk: a population-based matched cohort study.‏
670 ‎‡a Author's Increase in Fracture Risk Following Unintentional Weight Loss in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women.‏
670 ‎‡a Author's Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates‏
670 ‎‡a Author's Increased hip fracture and mortality in chronic kidney disease individuals: the importance of competing risks.‏
670 ‎‡a Author's Influence of the BsmI polymorphism of the vitamin D receptor gene on rheumatoid arthritis clinical activity‏
670 ‎‡a Author's International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study‏
670 ‎‡a Author's [Knowledge of the results of densitometry improves calcium intake in postmenopausal women]‏
670 ‎‡a Author's Leptin receptor (OB-R) gene expression in human primary osteoblasts: confirmation‏
670 ‎‡a Author's Management of glucocorticoid-induced osteoporosis.‏
670 ‎‡a Author's Management of osteoporosis of the oldest old.‏
670 ‎‡a Author's Measuring bone quality.‏
670 ‎‡a Author's Measuring quality of life in women with vertebral fractures due to osteoporosis: a comparison of the OQLQ and QUALEFFO.‏
670 ‎‡a Author's Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls.‏
670 ‎‡a Author's Microindentation for in vivo measurement of bone tissue mechanical properties in humans.‏
670 ‎‡a Author's MiRNA profiling of whole trabecular bone: identification of osteoporosis-related changes in MiRNAs in human hip bones‏
670 ‎‡a Author's Non-hip, non-spine fractures drive healthcare utilization following a fracture: the Global Longitudinal Study of Osteoporosis in Women (GLOW).‏
670 ‎‡a Author's Normative Data for Impact Microindentation for Australian Men: Cross-Sectional Data From the Geelong Osteoporosis Study‏
670 ‎‡a Author's Obesity and the Relative Risk of Knee Replacement Surgery in Patients With Knee Osteoarthritis: A Prospective Cohort Study.‏
670 ‎‡a Author's Obesity, health-care utilization, and health-related quality of life after fracture in postmenopausal women: Global Longitudinal Study of Osteoporosis in Women (GLOW).‏
670 ‎‡a Author's Oral Bisphosphonate Use and All-Cause Mortality in Patients With Moderate-Severe (Grade 3B-5D) Chronic Kidney Disease: A Population-Based Cohort Study‏
670 ‎‡a Author's [Osteoporitic fracture risk factors in Spain]‏
670 ‎‡a Author's Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment‏
670 ‎‡a Author's Parathyroid Hormone-Related Protein Analogs as Osteoporosis Therapies‏
670 ‎‡a Author's Patterns of anti-osteoporosis medication use among women at high risk of fracture: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).‏
670 ‎‡a Author's Polymorphisms and haplotypes across the osteoprotegerin gene associated with bone mineral density and osteoporotic fractures.‏
670 ‎‡a Author's Polymorphisms in the interleukin-6 receptor gene are associated with bone mineral density and body mass index in Spanish postmenopausal women‏
670 ‎‡a Author's Prediction of absolute risk of fragility fracture at 10 years in a Spanish population: validation of the WHO FRAX ™ tool in Spain.‏
670 ‎‡a Author's Prediction of absolute risk of non-spinal fractures using clinical risk factors and heel quantitative ultrasound.‏
670 ‎‡a Author's Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study.‏
670 ‎‡a Author's Prevalence of osteoporosis and fractures among women prescribed osteoporosis medication in five European countries: the POSSIBLE EU® study‏
670 ‎‡a Author's Prevalence of vertebral fracture in postmenopausal women with lumbar osteopenia using MorphoXpressSR‏
670 ‎‡a Author's Prevalence of vertebral fracture in postmenopausal women with lumbar osteopenia using MorphoXpressSR (OSTEOXPRESS Study)‏
670 ‎‡a Author's Probability of fractures predicted by FRAX® and observed incidence in the Spanish ECOSAP Study cohort.‏
670 ‎‡a Author's Promoter 2 -1025 T/C Polymorphism in the RUNX2 Gene Is Associated with Femoral Neck BMD in Spanish Postmenopausal Women‏
670 ‎‡a Author's Radiofrequency echographic multi-spectrometry for the in-vivo assessment of bone strength: state of the art-outcomes of an expert consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis a‏
670 ‎‡a Author's Real-Life and RCT Participants: Alendronate Users Versus FITs' Trial Eligibility Criterion‏
670 ‎‡a Author's Recommendations for an update of the current‏
670 ‎‡a Author's Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men.‏
670 ‎‡a Author's Regional and age-related variations in the proportions of hip fractures and major fractures among postmenopausal women: the Global Longitudinal Study of Osteoporosis in Women.‏
670 ‎‡a Author's Relationship among densitometry, bone histomorphometry, and histologic stage in idiopathic myelofibrosis‏
670 ‎‡a Author's Relationship between mortality and BMI after fracture: a population-based study of men and women aged ≥40 years.‏
670 ‎‡a Author's Response to comments on: Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis‏
670 ‎‡a Author's Risk factors for osteoporosis and osteoporotic fractures in a series of 5,195 women older than 65 years‏
670 ‎‡a Author's Risk factors for prediction of inadequate response to antiresorptives‏
670 ‎‡a Author's Romosozumab in postmenopausal women with low bone mineral density.‏
670 ‎‡a Author's Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a bi-national cohort analysis‏
670 ‎‡a Author's Selective estrogen receptor modulators (SERMS).‏
670 ‎‡a Author's Self-perception of fracture risk: what can it tell us?‏
670 ‎‡a Author's Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista‏
670 ‎‡a Author's Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.‏
670 ‎‡a Author's Socio-economic status and the risk of developing hand, hip or knee osteoarthritis: a region-wide ecological study.‏
670 ‎‡a Author's Socioeconomic status and its association with the risk of developing hip fractures: a region-wide ecological study.‏
670 ‎‡a Author's Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels.‏
670 ‎‡a Author's Teriparatide for glucocorticoid-induced osteoporosis‏
670 ‎‡a Author's The association between fracture and obesity is site-dependent: A population-based study in postmenopausal women‏
670 ‎‡a Author's The ECOS-16 questionnaire for the evaluation of health related quality of life in post-menopausal women with osteoporosis‏
670 ‎‡a Author's The effect of teriparatide [human parathyroid hormone‏
670 ‎‡a Author's The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.‏
670 ‎‡a Author's The Global Longitudinal Study of Osteoporosis in Women‏
670 ‎‡a Author's The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design.‏
670 ‎‡a Author's The impact of common co-morbidities‏
670 ‎‡a Author's The impact of common co-morbidities (as measured using the Charlson index) on hip fracture risk in elderly men: a population-based cohort study‏
670 ‎‡a Author's The relevance of biomaterials to the prevention and treatment of osteoporosis.‏
670 ‎‡a Author's The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).‏
670 ‎‡a Author's The tissue diagnostic instrument.‏
670 ‎‡a Author's Treatment failure in osteoporosis‏
670 ‎‡a Author's Treatment of osteoporosis in men‏
670 ‎‡a Author's Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography.‏
670 ‎‡a Author's Two new single-nucleotide polymorphisms in the COL1A1 upstream regulatory region and their relationship to bone mineral density.‏
670 ‎‡a Author's Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review‏
670 ‎‡a Author's Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study‏
670 ‎‡a Author's Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study.‏
670 ‎‡a Author's When, where and how osteoporosis-associated fractures occur: an analysis from the Global Longitudinal Study of Osteoporosis in Women (GLOW)‏
670 ‎‡a wikidata authority control‏ ‎‡u https://viaf.org/processed/BNE|XX1125518‏
670 ‎‡a wikidata authority control‏ ‎‡u https://viaf.org/viaf/86829678‏
909 ‎‡a (orcid) 0000000181620209‏ ‎‡9 1‏
919 ‎‡a bonematerialstrengthisassociatedwitharealbmdbutnotwithprevalentfracturesinolderwomen‏ ‎‡A Bone material strength is associated with areal BMD but not with prevalent fractures in older women‏ ‎‡9 1‏
919 ‎‡a haplotypebasedanalysisofthelrp5geneinrelationtoosteoporosisphenotypesinspanishpostmenopausalwomen‏ ‎‡A A Haplotype-Based Analysis of theLRP5Gene in Relation to Osteoporosis Phenotypes in Spanish Postmenopausal Women‏ ‎‡9 1‏
919 ‎‡a metaanalysisoftheassociationoffractureriskandbodymassindexinwomen‏ ‎‡A A meta-analysis of the association of fracture risk and body mass index in women‏ ‎‡9 1‏
919 ‎‡a newsnpinanegativeregulatoryregionofthecyp19a1geneisassociatedwithlumbarspinebmdinpostmenopausalwomen‏ ‎‡A A new SNP in a negative regulatory region of the CYP19A1 gene is associated with lumbar spine BMD in postmenopausal women.‏ ‎‡9 1‏
919 ‎‡a adversereactionsanddrugdruginteractionsinthemanagementofwomenwithpostmenopausalosteoporosis‏ ‎‡A Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis‏ ‎‡9 1‏
919 ‎‡a airelatedbmdvariationinactualpracticeconditionsaprospectivecohortstudy‏ ‎‡A AI-related BMD variation in actual practice conditions: A prospective cohort study.‏ ‎‡9 1‏
919 ‎‡a alendronateandetidronatedonotregulateinterleukin6and11synthesisinnormalhumanosteoblastsinculture‏ ‎‡A Alendronate and etidronate do not regulate interleukin 6 and 11 synthesis in normal human osteoblasts in culture.‏ ‎‡9 1‏
919 ‎‡a algorithmfortheuseofbiochemicalmarkersofboneturnoverinthediagnosisassessmentandfollowupoftreatmentforosteoporosis‏ ‎‡A Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis‏ ‎‡9 1‏
919 ‎‡a increasedrateoffallingleadstoariseinfractureriskinpostmenopausalwomenwithselfreportedosteoarthritisaprospectivemultinationalcohortstudyglow‏ ‎‡A An increased rate of falling leads to a rise in fracture risk in postmenopausal women with self-reported osteoarthritis: a prospective multinational cohort study (GLOW)‏ ‎‡9 1‏
919 ‎‡a analysesofrankandranklinthepostgwascontextfunctionalevidenceofvitamin500stimulationthrougharankldistalregion‏ ‎‡A Analyses of RANK and RANKL in the post-GWAS context: functional evidence of vitamin D stimulation through a RANKL distal region.‏ ‎‡9 1‏
919 ‎‡a analysisof3functionalpolymorphismsinrelationtoosteoporosisphenotypesreplicationinaspanishcohort‏ ‎‡A Analysis of three functional polymorphisms in relation to osteoporosis phenotypes: replication in a Spanish cohort.‏ ‎‡9 1‏
919 ‎‡a ankylosingspondylitisconferssubstantiallyincreasedriskofclinicalspinefracturesanationwidecasecontrolstudy‏ ‎‡A Ankylosing spondylitis confers substantially increased risk of clinical spine fractures: a nationwide case-control study.‏ ‎‡9 1‏
919 ‎‡a ankylosingspondylitisisassociatedwithanincreasedriskofvertebralandnonvertebralclinicalfracturesapopulationbasedcohortstudy‏ ‎‡A Ankylosing spondylitis is associated with an increased risk of vertebral and nonvertebral clinical fractures: a population-based cohort study.‏ ‎‡9 1‏
919 ‎‡a applicationsofanewhandheldreferencepointindentationinstrumentmeasuringbonematerialstrength‏ ‎‡A Applications of a New Handheld Reference Point Indentation Instrument Measuring Bone Material Strength‏ ‎‡9 1‏
919 ‎‡a arethehighhipfractureratesamongnorwegianwomenexplainedbyimpairedbonematerialproperties‏ ‎‡A Are the High Hip Fracture Rates Among Norwegian Women Explained by Impaired Bone Material Properties?‏ ‎‡9 1‏
919 ‎‡a associationbetweencollesfractureandlowbonemassagebaseddifferencesinpostmenopausalwomen‏ ‎‡A Association between Colles' fracture and low bone mass: age-based differences in postmenopausal women‏ ‎‡9 1‏
919 ‎‡a balancingbenefitsandrisksofglucocorticoidsinrheumaticdiseasesandotherinflammatoryjointdisordersnewinsightsfromemergingdataanexpertconsensuspaperfromtheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisando‏ ‎‡A Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and O‏ ‎‡9 1‏
919 ‎‡a bisphosphonates‏ ‎‡A Bisphosphonates.‏ ‎‡9 1‏
919 ‎‡a bonedensitymicroarchitectureandtissuequalitylongtermafterkidneytransplant‏ ‎‡A Bone Density, Microarchitecture, and Tissue Quality Long-term After Kidney Transplant.‏ ‎‡9 1‏
919 ‎‡a bonehealthinaprospectivecohortofpostmenopausalwomenreceivingaromataseinhibitorsforearlybreastcancer‏ ‎‡A Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer.‏ ‎‡9 1‏
919 ‎‡a bonemassofa113yearoldman‏ ‎‡A Bone Mass of a 113-Year-Old Man‏ ‎‡9 1‏
919 ‎‡a bonemassvitamin500deficiencyandhyperparathyroidismincongestiveheartfailure‏ ‎‡A Bone mass, vitamin D deficiency and hyperparathyroidism in congestive heart failure.‏ ‎‡9 1‏
919 ‎‡a bonemetabolismandhistomorphometricchangesinrheumatoidarthritis‏ ‎‡A Bone metabolism and histomorphometric changes in rheumatoid arthritis‏ ‎‡9 1‏
919 ‎‡a bonemineraldensityreferralfordualenergy10rayabsorptiometryusingquantitativeultrasoundasaprescreeningtoolinpostmenopausalwomenfromthegeneralpopulationacosteffectivenessanalysis‏ ‎‡A Bone mineral density referral for dual-energy X-ray absorptiometry using quantitative ultrasound as a prescreening tool in postmenopausal women from the general population: a cost-effectiveness analysis‏ ‎‡9 1‏
919 ‎‡a bonetissuepropertiesmeasurementbyreferencepointindentationinglucocorticoidinducedosteoporosis‏ ‎‡A Bone Tissue Properties Measurement by Reference Point Indentation in Glucocorticoid-Induced Osteoporosis‏ ‎‡9 1‏
919 ‎‡a briefreporthivinfectionisassociatedwithworsebonematerialpropertiesindependentlyofbonemineraldensity‏ ‎‡A Brief Report: HIV Infection Is Associated With Worse Bone Material Properties, Independently of Bone Mineral Density.‏ ‎‡9 1‏
919 ‎‡a burdenofnonhipnonvertebralfracturesonqualityoflifeinpostmenopausalwomenthegloballongitudinalstudyofosteoporosisinwomenglow‏ ‎‡A Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW)‏ ‎‡9 1‏
919 ‎‡a burdenofpelvisfractureapopulationbasedstudyofincidencehospitalisationandmortality‏ ‎‡A Burden of pelvis fracture: a population-based study of incidence, hospitalisation and mortality.‏ ‎‡9 1‏
919 ‎‡a changingtrendsintheepidemiologyofhipfractureinspain‏ ‎‡A Changing trends in the epidemiology of hip fracture in Spain.‏ ‎‡9 1‏
919 ‎‡a characteristicsassociatedwithantiosteoporosismedicationusedatafromthegloballongitudinalstudyofosteoporosisinwomenglowusacohort‏ ‎‡A Characteristics associated with anti-osteoporosis medication use: data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort.‏ ‎‡9 1‏
919 ‎‡a circulatingsclerostinandestradiollevelsareassociatedwithinadequateresponsetobisphosphonatesinpostmenopausalwomenwithosteoporosis‏ ‎‡A Circulating sclerostin and estradiol levels are associated with inadequate response to bisphosphonates in postmenopausal women with osteoporosis.‏ ‎‡9 1‏
919 ‎‡a col1a1esr1vdrandtgfb1polymorphismsandhaplotypesinrelationtobmdinspanishpostmenopausalwomen‏ ‎‡A COL1A1, ESR1, VDR and TGFB1 polymorphisms and haplotypes in relation to BMD in Spanish postmenopausal women‏ ‎‡9 1‏
919 ‎‡a col1a1haplotypesandhipfracture‏ ‎‡A COL1A1 haplotypes and hip fracture.‏ ‎‡9 1‏
919 ‎‡a comparisonoftheeffectsofosseinhydroxyapatitecomplexandcalciumcarbonateonbonemetabolisminwomenwithsenileosteoporosisarandomizedopenlabelparallelgroupcontrolledprospectivestudy‏ ‎‡A Comparison of the effects of ossein-hydroxyapatite complex and calcium carbonate on bone metabolism in women with senile osteoporosis: a randomized, open-label, parallel-group, controlled, prospective study.‏ ‎‡9 1‏
919 ‎‡a correctionlargescaleevidencefortheeffectofthecolia1sp1polymorphismonosteoporosisoutcomesthegenomosstudy‏ ‎‡A Correction: Large-Scale Evidence for the Effect of the COLIA1 Sp1 Polymorphism on Osteoporosis Outcomes: The GENOMOS Study‏ ‎‡9 1‏
919 ‎‡a currentandfuturetreatmentsofsecondaryosteoporosis‏ ‎‡A Current and future treatments of secondary osteoporosis‏ ‎‡9 1‏
919 ‎‡a cyp11a1expressioninboneisassociatedwitharomataseinhibitorrelatedboneloss‏ ‎‡A CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss.‏ ‎‡9 1‏
919 ‎‡a developmentofashortosteoporosisqualityoflifequestionnairebyequatingitemsfrom2existinginstruments‏ ‎‡A Development of a short osteoporosis quality of life questionnaire by equating items from two existing instruments.‏ ‎‡9 1‏
919 ‎‡a developmentoftheecos16clinicalquestionnairefortheassessmentofthequalityoflifeinpatientswithosteoporosis‏ ‎‡A [Development of the ECOS-16 clinical questionnaire for the assessment of the quality of life in patients with osteoporosis]‏ ‎‡9 1‏
919 ‎‡a discriminativecapacityofcalcanealquantitativeultrasoundandofosteoporosisandfractureriskfactorsinpostmenopausalwomenwithosteoporoticfractures‏ ‎‡A Discriminative capacity of calcaneal quantitative ultrasound and of osteoporosis and fracture risk factors in postmenopausal women with osteoporotic fractures.‏ ‎‡9 1‏
919 ‎‡a drugutilizationinpatientswithoaapopulationbasedstudy‏ ‎‡A Drug utilization in patients with OA: a population-based study.‏ ‎‡9 1‏
919 ‎‡a early1yeardiscontinuationofdifferentantiosteoporosismedicationscomparedapopulationbasedcohortstudy‏ ‎‡A Early (1-year) Discontinuation of Different Anti-osteoporosis Medications Compared: A Population-Based Cohort Study‏ ‎‡9 1‏
919 ‎‡a effectofil1betapge2andtgfbeta1ontheexpressionofopgandranklinnormalandosteoporoticprimaryhumanosteoblasts‏ ‎‡A Effect of IL-1beta, PGE(2), and TGF-beta1 on the expression of OPG and RANKL in normal and osteoporotic primary human osteoblasts.‏ ‎‡9 1‏
919 ‎‡a effectoftobaccosmokingonleptinserumlevelsanditsrelationshipwithsteroidhormonesandbonemineraldensity‏ ‎‡A [Effect of tobacco smoking on leptin serum levels and its relationship with steroid hormones and bone mineral density]‏ ‎‡9 1‏
919 ‎‡a effectsofraloxifenehydrochlorideonbonemineraldensitybonemetabolismandserumlipidsinchinesepostmenopausalwomenwithosteoporosisamulticenterrandomizedplacebocontrolledclinicaltrial‏ ‎‡A Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.‏ ‎‡9 1‏
919 ‎‡a empiricallybasedcompositefracturepredictionmodelfromthegloballongitudinalstudyofosteoporosisinpostmenopausalwomen‏ ‎‡A Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women‏ ‎‡9 1‏
919 ‎‡a empiricallybasedcompositefracturepredictionmodelfromthegloballongitudinalstudyofosteoporosisinpostmenopausalwomenglow‏ ‎‡A Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW).‏ ‎‡9 1‏
919 ‎‡a erratumtotheroleofdietaryproteinandvitamin500inmaintainingmusculoskeletalhealthinpostmenopausalwomenaconsensusstatementfromtheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisandosteoarthritis‏ ‎‡A Erratum to “The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis‏ ‎‡9 1‏
919 ‎‡a erratumtotheroleofdietaryproteinandvitamin500inmaintainingmusculoskeletalhealthinpostmenopausalwomenaconsensusstatementfromtheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisandosteoarthritisesceoma‏ ‎‡A Erratum to “The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)” [Ma‏ ‎‡9 1‏
919 ‎‡a evaluationofcalcanealquantitativeultrasoundinaprimarycaresettingasascreeningtoolforosteoporosisinpostmenopausalwomen‏ ‎‡A Evaluation of calcaneal quantitative ultrasound in a primary care setting as a screening tool for osteoporosis in postmenopausal women‏ ‎‡9 1‏
919 ‎‡a failuretoperceiveincreasedriskoffractureinwomen55yearsandolderthegloballongitudinalstudyofosteoporosisinwomen‏ ‎‡A Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women‏ ‎‡9 1‏
919 ‎‡a failuretoperceiveincreasedriskoffractureinwomen55yearsandolderthegloballongitudinalstudyofosteoporosisinwomenglow‏ ‎‡A Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW).‏ ‎‡9 1‏
919 ‎‡a fragilitynonspinalfracturesinacohortof5201womenaged65yearsandolderduringa3yearfollowup‏ ‎‡A [Fragility non-spinal fractures in a cohort of 5,201 women aged 65 years and older during a 3-year follow-up]‏ ‎‡9 1‏
919 ‎‡a fraxthresholdstoidentifypeoplewithhighorlowriskofosteoporoticfractureinspanishfemalepopulation‏ ‎‡A FRAX® thresholds to identify people with high or low risk of osteoporotic fracture in Spanish female population‏ ‎‡9 1‏
919 ‎‡a functionalanalysisofthe1316piiand14promotersofcyp19aromatasegeneinhumanosteoblastsandtheirroleinvitamin500anddexamethasonestimulation‏ ‎‡A Functional analysis of the I.3, I.6, pII and I.4 promoters of CYP19 (aromatase) gene in human osteoblasts and their role in vitamin D and dexamethasone stimulation.‏ ‎‡9 1‏
919 ‎‡a functionalassessmentofcodingandregulatoryvariantsfromthe1dkk11locus‏ ‎‡A Functional Assessment of Coding and Regulatory Variants From the <i>DKK1</i> Locus‏ ‎‡9 1‏
919 ‎‡a geneticanalysisofhighbonemasscasesfromthebarcoscohortofspanishpostmenopausalwomen‏ ‎‡A Genetic analysis of high bone mass cases from the BARCOS cohort of Spanish postmenopausal women‏ ‎‡9 1‏
919 ‎‡a hivinfectionbonemetabolismandfractures‏ ‎‡A HIV infection, bone metabolism, and fractures.‏ ‎‡9 1‏
919 ‎‡a invitroperformanceofceramiccoatingsobtainedbyhighvelocityoxyfuelspray‏ ‎‡A In vitro performance of ceramic coatings obtained by high velocity oxy-fuel spray‏ ‎‡9 1‏
919 ‎‡a inadequateresponderstoosteoporosistreatmentproposalforanoperationaldefinition‏ ‎‡A Inadequate responders to osteoporosis treatment: proposal for an operational definition.‏ ‎‡9 1‏
919 ‎‡a incidenceandpredictorsofmultiplefracturesdespitehighadherencetooralbisphosphonatesabinationalpopulationbasedcohortstudy‏ ‎‡A Incidence and Predictors of Multiple Fractures Despite High Adherence to Oral Bisphosphonates: A Binational Population-Based Cohort Study.‏ ‎‡9 1‏
919 ‎‡a incidenceandriskfactorsforclinicallydiagnosedkneehipandhandosteoarthritisinfluencesofagegenderandosteoarthritisaffectingotherjoints‏ ‎‡A Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of age, gender and osteoarthritis affecting other joints.‏ ‎‡9 1‏
919 ‎‡a incidenttype2diabetesandhipfractureriskapopulationbasedmatchedcohortstudy‏ ‎‡A Incident type 2 diabetes and hip fracture risk: a population-based matched cohort study.‏ ‎‡9 1‏
919 ‎‡a increaseinfractureriskfollowingunintentionalweightlossinpostmenopausalwomenthegloballongitudinalstudyofosteoporosisinwomen‏ ‎‡A Increase in Fracture Risk Following Unintentional Weight Loss in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women.‏ ‎‡9 1‏
919 ‎‡a increasedfractureriskinwomentreatedwitharomataseinhibitorsversustamoxifenbeneficialeffectofbisphosphonates‏ ‎‡A Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates‏ ‎‡9 1‏
919 ‎‡a increasedhipfractureandmortalityinchronickidneydiseaseindividualstheimportanceofcompetingrisks‏ ‎‡A Increased hip fracture and mortality in chronic kidney disease individuals: the importance of competing risks.‏ ‎‡9 1‏
919 ‎‡a influenceofthebsmipolymorphismofthevitamin500receptorgeneonrheumatoidarthritisclinicalactivity‏ ‎‡A Influence of the BsmI polymorphism of the vitamin D receptor gene on rheumatoid arthritis clinical activity‏ ‎‡9 1‏
919 ‎‡a internationalmanagementofbonehealthinglucocorticoidexposedindividualsintheobservationalglowstudy‏ ‎‡A International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study‏ ‎‡9 1‏
919 ‎‡a knowledgeoftheresultsofdensitometryimprovescalciumintakeinpostmenopausalwomen‏ ‎‡A [Knowledge of the results of densitometry improves calcium intake in postmenopausal women]‏ ‎‡9 1‏
919 ‎‡a leptinreceptorobrgeneexpressioninhumanprimaryosteoblastsconfirmation‏ ‎‡A Leptin receptor (OB-R) gene expression in human primary osteoblasts: confirmation‏ ‎‡9 1‏
919 ‎‡a managementofglucocorticoidinducedosteoporosis‏ ‎‡A Management of glucocorticoid-induced osteoporosis.‏ ‎‡9 1‏
919 ‎‡a managementofosteoporosisoftheoldestold‏ ‎‡A Management of osteoporosis of the oldest old.‏ ‎‡9 1‏
919 ‎‡a measuringbonequality‏ ‎‡A Measuring bone quality.‏ ‎‡9 1‏
919 ‎‡a measuringqualityoflifeinwomenwithvertebralfracturesduetoosteoporosisacomparisonoftheoqlqandqualeffo‏ ‎‡A Measuring quality of life in women with vertebral fractures due to osteoporosis: a comparison of the OQLQ and QUALEFFO.‏ ‎‡9 1‏
919 ‎‡a microindentationforinvivomeasurementofbonetissuematerialpropertiesinatypicalfemoralfracturepatientsandcontrols‏ ‎‡A Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls.‏ ‎‡9 1‏
919 ‎‡a microindentationforinvivomeasurementofbonetissuemechanicalpropertiesinhumans‏ ‎‡A Microindentation for in vivo measurement of bone tissue mechanical properties in humans.‏ ‎‡9 1‏
919 ‎‡a mirnaprofilingofwholetrabecularboneidentificationofosteoporosisrelatedchangesinmirnasinhumanhipbones‏ ‎‡A MiRNA profiling of whole trabecular bone: identification of osteoporosis-related changes in MiRNAs in human hip bones‏ ‎‡9 1‏
919 ‎‡a nonhipnonspinefracturesdrivehealthcareutilizationfollowingafracturethegloballongitudinalstudyofosteoporosisinwomenglow‏ ‎‡A Non-hip, non-spine fractures drive healthcare utilization following a fracture: the Global Longitudinal Study of Osteoporosis in Women (GLOW).‏ ‎‡9 1‏
919 ‎‡a normativedataforimpactmicroindentationforaustralianmencrosssectionaldatafromthegeelongosteoporosisstudy‏ ‎‡A Normative Data for Impact Microindentation for Australian Men: Cross-Sectional Data From the Geelong Osteoporosis Study‏ ‎‡9 1‏
919 ‎‡a obesityandtherelativeriskofkneereplacementsurgeryinpatientswithkneeosteoarthritisaprospectivecohortstudy‏ ‎‡A Obesity and the Relative Risk of Knee Replacement Surgery in Patients With Knee Osteoarthritis: A Prospective Cohort Study.‏ ‎‡9 1‏
919 ‎‡a obesityhealthcareutilizationandhealthrelatedqualityoflifeafterfractureinpostmenopausalwomengloballongitudinalstudyofosteoporosisinwomenglow‏ ‎‡A Obesity, health-care utilization, and health-related quality of life after fracture in postmenopausal women: Global Longitudinal Study of Osteoporosis in Women (GLOW).‏ ‎‡9 1‏
919 ‎‡a oralbisphosphonateuseandallcausemortalityinpatientswithmoderateseveregrade3b5dchronickidneydiseaseapopulationbasedcohortstudy‏ ‎‡A Oral Bisphosphonate Use and All-Cause Mortality in Patients With Moderate-Severe (Grade 3B-5D) Chronic Kidney Disease: A Population-Based Cohort Study‏ ‎‡9 1‏
919 ‎‡a osteoporiticfractureriskfactorsinspain‏ ‎‡A [Osteoporitic fracture risk factors in Spain]‏ ‎‡9 1‏
919 ‎‡a osteoporoticfracturerateamongwomenwithatleast1yearofadherencetoosteoporosistreatment‏ ‎‡A Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment‏ ‎‡9 1‏
919 ‎‡a parathyroidhormonerelatedproteinanalogsasosteoporosistherapies‏ ‎‡A Parathyroid Hormone-Related Protein Analogs as Osteoporosis Therapies‏ ‎‡9 1‏
919 ‎‡a patternsofantiosteoporosismedicationuseamongwomenathighriskoffracturefindingsfromthegloballongitudinalstudyofosteoporosisinwomenglow‏ ‎‡A Patterns of anti-osteoporosis medication use among women at high risk of fracture: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).‏ ‎‡9 1‏
919 ‎‡a polymorphismsandhaplotypesacrosstheosteoprotegeringeneassociatedwithbonemineraldensityandosteoporoticfractures‏ ‎‡A Polymorphisms and haplotypes across the osteoprotegerin gene associated with bone mineral density and osteoporotic fractures.‏ ‎‡9 1‏
919 ‎‡a polymorphismsintheinterleukin6receptorgeneareassociatedwithbonemineraldensityandbodymassindexinspanishpostmenopausalwomen‏ ‎‡A Polymorphisms in the interleukin-6 receptor gene are associated with bone mineral density and body mass index in Spanish postmenopausal women‏ ‎‡9 1‏
919 ‎‡a predictionofabsoluteriskoffragilityfractureat10yearsinaspanishpopulationvalidationofthewhofraxtmtoolinspain‏ ‎‡A Prediction of absolute risk of fragility fracture at 10 years in a Spanish population: validation of the WHO FRAX ™ tool in Spain.‏ ‎‡9 1‏
919 ‎‡a predictionofabsoluteriskofnonspinalfracturesusingclinicalriskfactorsandheelquantitativeultrasound‏ ‎‡A Prediction of absolute risk of non-spinal fractures using clinical risk factors and heel quantitative ultrasound.‏ ‎‡9 1‏
919 ‎‡a predictorsoffracturewhileontreatmentwithoralbisphosphonatesapopulationbasedcohortstudy‏ ‎‡A Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study.‏ ‎‡9 1‏
919 ‎‡a prevalenceofosteoporosisandfracturesamongwomenprescribedosteoporosismedicationin5europeancountriesthepossibleeustudy‏ ‎‡A Prevalence of osteoporosis and fractures among women prescribed osteoporosis medication in five European countries: the POSSIBLE EU® study‏ ‎‡9 1‏
919 ‎‡a prevalenceofvertebralfractureinpostmenopausalwomenwithlumbarosteopeniausingmorphoxpresssr‏ ‎‡A Prevalence of vertebral fracture in postmenopausal women with lumbar osteopenia using MorphoXpressSR‏ ‎‡9 1‏
919 ‎‡a prevalenceofvertebralfractureinpostmenopausalwomenwithlumbarosteopeniausingmorphoxpresssrosteoxpressstudy‏ ‎‡A Prevalence of vertebral fracture in postmenopausal women with lumbar osteopenia using MorphoXpressSR (OSTEOXPRESS Study)‏ ‎‡9 1‏
919 ‎‡a probabilityoffracturespredictedbyfraxandobservedincidenceinthespanishecosapstudycohort‏ ‎‡A Probability of fractures predicted by FRAX® and observed incidence in the Spanish ECOSAP Study cohort.‏ ‎‡9 1‏
919 ‎‡a promoter21025t100polymorphismintherunx2geneisassociatedwithfemoralneckbmdinspanishpostmenopausalwomen‏ ‎‡A Promoter 2 -1025 T/C Polymorphism in the RUNX2 Gene Is Associated with Femoral Neck BMD in Spanish Postmenopausal Women‏ ‎‡9 1‏
919 ‎‡a radiofrequencyechographicmultispectrometryfortheinvivoassessmentofbonestrengthstateoftheartoutcomesofanexpertconsensusmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisa‏ ‎‡A Radiofrequency echographic multi-spectrometry for the in-vivo assessment of bone strength: state of the art-outcomes of an expert consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis a‏ ‎‡9 1‏
919 ‎‡a reallifeandrctparticipantsalendronateusersversusfitstrialeligibilitycriterion‏ ‎‡A Real-Life and RCT Participants: Alendronate Users Versus FITs' Trial Eligibility Criterion‏ ‎‡9 1‏
919 ‎‡a recommendationsforanupdateofthecurrent‏ ‎‡A Recommendations for an update of the current‏ ‎‡9 1‏
919 ‎‡a recommendationsforanupdateofthecurrent2001regulatoryrequirementsforregistrationofdrugstobeusedinthetreatmentofosteoporosisinpostmenopausalwomenandinmen‏ ‎‡A Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men.‏ ‎‡9 1‏
919 ‎‡a regionalandagerelatedvariationsintheproportionsofhipfracturesandmajorfracturesamongpostmenopausalwomenthegloballongitudinalstudyofosteoporosisinwomen‏ ‎‡A Regional and age-related variations in the proportions of hip fractures and major fractures among postmenopausal women: the Global Longitudinal Study of Osteoporosis in Women.‏ ‎‡9 1‏
919 ‎‡a relationshipamongdensitometrybonehistomorphometryandhistologicstageinidiopathicmyelofibrosis‏ ‎‡A Relationship among densitometry, bone histomorphometry, and histologic stage in idiopathic myelofibrosis‏ ‎‡9 1‏
919 ‎‡a relationshipbetweenmortalityandbmiafterfractureapopulationbasedstudyofmenandwomenaged40years‏ ‎‡A Relationship between mortality and BMI after fracture: a population-based study of men and women aged ≥40 years.‏ ‎‡9 1‏
919 ‎‡a responsetocommentsonresultsofindirectandmixedtreatmentcomparisonoffractureefficacyforosteoporosistreatmentsametaanalysis‏ ‎‡A Response to comments on: Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis‏ ‎‡9 1‏
919 ‎‡a riskfactorsforosteoporosisandosteoporoticfracturesinaseriesof5195womenolderthan65years‏ ‎‡A Risk factors for osteoporosis and osteoporotic fractures in a series of 5,195 women older than 65 years‏ ‎‡9 1‏
919 ‎‡a riskfactorsforpredictionofinadequateresponsetoantiresorptives‏ ‎‡A Risk factors for prediction of inadequate response to antiresorptives‏ ‎‡9 1‏
919 ‎‡a romosozumabinpostmenopausalwomenwithlowbonemineraldensity‏ ‎‡A Romosozumab in postmenopausal women with low bone mineral density.‏ ‎‡9 1‏
919 ‎‡a safetyoforalbisphosphonatesinmoderatetoseverechronickidneydiseaseabinationalcohortanalysis‏ ‎‡A Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a bi-national cohort analysis‏ ‎‡9 1‏
919 ‎‡a selectiveestrogenreceptormodulatorsserms‏ ‎‡A Selective estrogen receptor modulators (SERMS).‏ ‎‡9 1‏
919 ‎‡a selfperceptionoffractureriskwhatcanittellus‏ ‎‡A Self-perception of fracture risk: what can it tell us?‏ ‎‡9 1‏
919 ‎‡a skeletaleffectsofraloxifeneafter8yearsresultsfromthecontinuingoutcomesrelevanttoevista‏ ‎‡A Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista‏ ‎‡9 1‏
919 ‎‡a skeletaleffectsofraloxifeneafter8yearsresultsfromthecontinuingoutcomesrelevanttoevistacorestudy‏ ‎‡A Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.‏ ‎‡9 1‏
919 ‎‡a socioeconomicstatusandtheriskofdevelopinghandhiporkneeosteoarthritisaregionwideecologicalstudy‏ ‎‡A Socio-economic status and the risk of developing hand, hip or knee osteoarthritis: a region-wide ecological study.‏ ‎‡9 1‏
919 ‎‡a socioeconomicstatusanditsassociationwiththeriskofdevelopinghipfracturesaregionwideecologicalstudy‏ ‎‡A Socioeconomic status and its association with the risk of developing hip fractures: a region-wide ecological study.‏ ‎‡9 1‏
919 ‎‡a switchingfromtenofovirtoabacavirinhiv1infectedpatientswithlowbonemineraldensitychangesinboneturnovermarkersandcirculatingsclerostinlevels‏ ‎‡A Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels.‏ ‎‡9 1‏
919 ‎‡a teriparatideforglucocorticoidinducedosteoporosis‏ ‎‡A Teriparatide for glucocorticoid-induced osteoporosis‏ ‎‡9 1‏
919 ‎‡a associationbetweenfractureandobesityissitedependentapopulationbasedstudyinpostmenopausalwomen‏ ‎‡A The association between fracture and obesity is site-dependent: A population-based study in postmenopausal women‏ ‎‡9 1‏
919 ‎‡a ecos16questionnairefortheevaluationofhealthrelatedqualityoflifeinpostmenopausalwomenwithosteoporosis‏ ‎‡A The ECOS-16 questionnaire for the evaluation of health related quality of life in post-menopausal women with osteoporosis‏ ‎‡9 1‏
919 ‎‡a effectofteriparatidehumanparathyroidhormone‏ ‎‡A The effect of teriparatide [human parathyroid hormone‏ ‎‡9 1‏
919 ‎‡a effectofteriparatidetherapyonbonedensityinmenwithosteoporosis‏ ‎‡A The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.‏ ‎‡9 1‏
919 ‎‡a globallongitudinalstudyofosteoporosisinwomen‏ ‎‡A The Global Longitudinal Study of Osteoporosis in Women‏ ‎‡9 1‏
919 ‎‡a globallongitudinalstudyofosteoporosisinwomenglowrationaleandstudydesign‏ ‎‡A The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design.‏ ‎‡9 1‏
919 ‎‡a impactofcommoncomorbidities‏ ‎‡A The impact of common co-morbidities‏ ‎‡9 1‏
919 ‎‡a impactofcommoncomorbiditiesasmeasuredusingthecharlsonindexonhipfractureriskinelderlymenapopulationbasedcohortstudy‏ ‎‡A The impact of common co-morbidities (as measured using the Charlson index) on hip fracture risk in elderly men: a population-based cohort study‏ ‎‡9 1‏
919 ‎‡a relevanceofbiomaterialstothepreventionandtreatmentofosteoporosis‏ ‎‡A The relevance of biomaterials to the prevention and treatment of osteoporosis.‏ ‎‡9 1‏
919 ‎‡a roleofdietaryproteinandvitamin500inmaintainingmusculoskeletalhealthinpostmenopausalwomenaconsensusstatementfromtheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisandosteoarthritisesceo‏ ‎‡A The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).‏ ‎‡9 1‏
919 ‎‡a tissuediagnosticinstrument‏ ‎‡A The tissue diagnostic instrument.‏ ‎‡9 1‏
919 ‎‡a treatmentfailureinosteoporosis‏ ‎‡A Treatment failure in osteoporosis‏ ‎‡9 1‏
919 ‎‡a treatmentofosteoporosisinmen‏ ‎‡A Treatment of osteoporosis in men‏ ‎‡9 1‏
919 ‎‡a treatmentwithraloxifenefor2yearsincreasesvertebralbonemineraldensityasmeasuredbyvolumetricquantitativecomputedtomography‏ ‎‡A Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography.‏ ‎‡9 1‏
919 ‎‡a 2newsinglenucleotidepolymorphismsinthecol1a1upstreamregulatoryregionandtheirrelationshiptobonemineraldensity‏ ‎‡A Two new single-nucleotide polymorphisms in the COL1A1 upstream regulatory region and their relationship to bone mineral density.‏ ‎‡9 1‏
919 ‎‡a updateonlongtermtreatmentwithbisphosphonatesforpostmenopausalosteoporosisasystematicreview‏ ‎‡A Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review‏ ‎‡9 1‏
919 ‎‡a vitamin500thresholdtopreventaromataseinhibitorinducedarthralgiaaprospectivecohortstudy‏ ‎‡A Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study‏ ‎‡9 1‏
919 ‎‡a vitamin500thresholdtopreventaromataseinhibitorrelatedbonelossthebableprospectivecohortstudy‏ ‎‡A Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study.‏ ‎‡9 1‏
919 ‎‡a whenwhereandhowosteoporosisassociatedfracturesoccurananalysisfromthegloballongitudinalstudyofosteoporosisinwomenglow‏ ‎‡A When, where and how osteoporosis-associated fractures occur: an analysis from the Global Longitudinal Study of Osteoporosis in Women (GLOW)‏ ‎‡9 1‏
996 ‎‡2 BNE|XX1063960‏
996 ‎‡2 NUKAT|n 2004099237‏
996 ‎‡2 ISNI|0000000400889540‏
996 ‎‡2 LC|ns2017000538‏
996 ‎‡2 LC|no2010146120‏
996 ‎‡2 RERO|A024822054‏
996 ‎‡2 LC|no 00082866‏
996 ‎‡2 PLWABN|9810654838805606‏
996 ‎‡2 LC|n 79088825‏
996 ‎‡2 ARBABN|000073627‏
996 ‎‡2 DNB|1111645183‏
996 ‎‡2 ISNI|0000000031697331‏
996 ‎‡2 NDL|01196728‏
996 ‎‡2 RERO|A000029172‏
996 ‎‡2 BNF|12497717‏
996 ‎‡2 LC|no2012124145‏
996 ‎‡2 ISNI|0000000059496021‏
996 ‎‡2 BNE|XX5745031‏
996 ‎‡2 ISNI|000000010249724X‏
996 ‎‡2 BIBSYS|90510569‏
996 ‎‡2 BNE|XX5536459‏
996 ‎‡2 BNE|XX1734613‏
996 ‎‡2 BNCHL|10000000000000000086962‏
996 ‎‡2 ARBABN|000050324‏
996 ‎‡2 LC|ns2023002965‏
996 ‎‡2 BNE|XX5174034‏
996 ‎‡2 BNF|12476086‏
996 ‎‡2 BNC|981058517175806706‏
996 ‎‡2 ISNI|000000040017561X‏
996 ‎‡2 LC|no2010025176‏
996 ‎‡2 DNB|1056224215‏
996 ‎‡2 BNC|981058608148606706‏
996 ‎‡2 SUDOC|120155184‏
996 ‎‡2 LC|no 95019052‏
996 ‎‡2 PLWABN|9810573834505606‏
996 ‎‡2 ISNI|0000000028890018‏
996 ‎‡2 LC|n 93072187‏
996 ‎‡2 ISNI|0000000078281421‏
996 ‎‡2 BNE|XX1535661‏
996 ‎‡2 BNE|XX969198‏
996 ‎‡2 LC|n 91093309‏
996 ‎‡2 DNB|121430799X‏
996 ‎‡2 SUDOC|203349865‏
996 ‎‡2 BNE|XX1125518‏
996 ‎‡2 LC|n 2017022693‏
996 ‎‡2 BNE|XX1749221‏
996 ‎‡2 LIH|LNB:BO_e__v_;=B8‏
996 ‎‡2 ISNI|000000003771717X‏
996 ‎‡2 ARBABN|000071272‏
996 ‎‡2 BNE|XX960076‏
996 ‎‡2 ARBABN|000071271‏
996 ‎‡2 BNCHL|10000000000000000114272‏
996 ‎‡2 JPG|500289708‏
996 ‎‡2 BNE|XX870388‏
996 ‎‡2 PTBNP|1535078‏
996 ‎‡2 BNE|XX886253‏
996 ‎‡2 ISNI|0000000001665734‏
996 ‎‡2 BNE|XX822060‏
996 ‎‡2 ISNI|0000000059929894‏
996 ‎‡2 LC|n 85100049‏
996 ‎‡2 BNF|14030657‏
996 ‎‡2 SUDOC|080801293‏
996 ‎‡2 NYNYRILM|189111‏
996 ‎‡2 ISNI|0000000046567193‏
996 ‎‡2 ISNI|0000000060532448‏
996 ‎‡2 NTA|071913572‏
996 ‎‡2 DNB|1045948780‏
996 ‎‡2 PLWABN|9810536865205606‏
996 ‎‡2 PLWABN|9811801533505606‏
996 ‎‡2 ISNI|0000000059570762‏
996 ‎‡2 SUDOC|23783524X‏
996 ‎‡2 LC|nr 93047148‏
996 ‎‡2 DNB|1280540850‏
996 ‎‡2 SUDOC|030688442‏
996 ‎‡2 DNB|1283892278‏
996 ‎‡2 SUDOC|16605335X‏
996 ‎‡2 BNE|XX1068284‏
996 ‎‡2 BNE|XX1107009‏
996 ‎‡2 BNC|981058518727906706‏
996 ‎‡2 ISNI|000000007970641X‏
996 ‎‡2 BNE|XX904921‏
996 ‎‡2 NUKAT|n 2016078211‏
996 ‎‡2 KRNLK|KAC2020S3678‏
996 ‎‡2 BNC|981058513933406706‏
996 ‎‡2 JPG|500230611‏
996 ‎‡2 BNE|XX945194‏
996 ‎‡2 ISNI|0000000474754980‏
996 ‎‡2 RERO|A011840230‏
996 ‎‡2 BNE|XX4618014‏
996 ‎‡2 LC|no2008149228‏
996 ‎‡2 NTA|217826040‏
996 ‎‡2 ARBABN|000071287‏
996 ‎‡2 ARBABN|000071284‏
996 ‎‡2 BNF|12205410‏
996 ‎‡2 ISNI|0000000111697809‏
996 ‎‡2 BNE|XX953303‏
996 ‎‡2 BNC|981058514117606706‏
996 ‎‡2 ISNI|0000000059973596‏
996 ‎‡2 LC|no 94012978‏
996 ‎‡2 ISNI|0000000059531990‏
996 ‎‡2 ISNI|0000000441082639‏
996 ‎‡2 NUKAT|n 2002096677‏
996 ‎‡2 BAV|495_255452‏
996 ‎‡2 BNC|981061159161306706‏
996 ‎‡2 ISNI|0000000383231826‏
996 ‎‡2 BNE|XX983983‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏
998 ‎‡a Díez Pérez, Adolfo‏ ‎‡2 BNE|XX1125518‏ ‎‡3 suggested‏
998 ‎‡a Diez Pérez, Adolfo‏ ‎‡2 BNC|981058519127406706‏ ‎‡3 standard number‏